Royalty Pharma reported revenue of $674.14M and net income of $81.49M for the quarter ended Jun 2026, up 16.5% year over year. This income statement covers 29 quarters of results from Jun 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income StatementIncome Statement | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & Cost | |||||||||||||||||||||||||||||
| Interest expenses | |||||||||||||||||||||||||||||
| Interest ExpensesInterest Expense | 44.33M | 46.97M | 47.06M | 46.97M | 46.98M | 46.96M | 46.95M | 46.95M | 46.03M | 47.26M | 44.23M | 49.01M | 66.51M | 65.76M | 65.26M | 68.67M | 79.56M | 94.17M | 93.72M | 93.62M | |||||||||
| Net interest income | |||||||||||||||||||||||||||||
| Provision for Credit LossesProvisions | 137.84M | 266.51M | 184.62M | 105.71M | 305.06M | 308.85M | 118.80M | 241.23M | 277.14M | -76.51M | 583.60M | 212.43M | -227.60M | 164.04M | -127.14M | -203.94M | 12.14M | 23.11M | -197.49M | 268.22M | |||||||||
| Non-interest income | |||||||||||||||||||||||||||||
| Income - Equity | 2.75M | -38.02M | 0.40M | 0.74M | -3.25M | -6.86M | 34.61M | -0.77M | -5.22M | 0.27M | -14.15M | 1.70M | 10.41M | 31.65M | 6.44M | 2.69M | 15.95M | 4.01M | 21.76M | 4.08M | |||||||||
| Non-Interest Income - Total | 2.75M | -38.02M | 0.40M | 0.74M | -3.25M | -6.86M | 34.61M | -0.77M | -5.22M | 0.27M | -14.15M | 1.70M | 10.41M | 31.65M | 6.44M | 2.69M | 15.95M | 4.01M | 21.76M | 4.08M | |||||||||
| Revenue | 585.77M | 575.70M | 562.05M | 535.96M | 573.46M | 565.75M | 683.97M | 538.20M | 536.31M | 596.07M | 567.98M | 537.27M | 564.69M | 593.64M | 568.25M | 578.67M | 609.29M | 621.99M | 630.58M | 674.14M | |||||||||
| Operating Items | |||||||||||||||||||||||||||||
| Amortization - Intangibles | 5.80M | 5.80M | 5.67M | ||||||||||||||||||||||||||
| Selling, General & AdministrativeSG&A | 48.59M | 46.16M | 51.54M | 51.84M | 50.69M | 73.23M | 85.70M | 47.63M | 57.23M | 59.19M | 57.65M | 54.71M | 56.72M | 67.59M | 110.71M | 179.77M | 118.73M | 164.27M | 159.49M | 161.89M | |||||||||
| Other Non-Interest ExpenseOther Non-Int. Exp. | 228.34M | 370.33M | 285.12M | 106.32M | 330.56M | 975.18M | 119.30M | 241.73M | 327.64M | -76.01M | 584.10M | 212.93M | -227.10M | 164.54M | -76.64M | 189.10M | 63.40M | 69.34M | -91.95M | 379.14M | |||||||||
| Operating ExpensesOpex | 282.72M | 422.28M | 342.33M | 158.16M | 381.25M | 1,048.40M | 205.00M | 289.36M | 384.87M | -16.83M | 641.75M | 267.64M | -170.38M | 232.13M | 34.07M | 368.87M | 182.14M | 233.61M | 67.54M | 541.02M | |||||||||
| Non-operating items | |||||||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 12.26M | 10.64M | 9.53M | 10.92M | 14.03M | 43.85M | 16.70M | 25.65M | 23.44M | 6.50M | 7.42M | 13.38M | 17.51M | 9.04M | 11.29M | 8.33M | 6.90M | 7.07M | 6.23M | 5.13M | |||||||||
| Other Non Operating IncomeOther Non Op Inc. | -17.77M | -4.92M | -1.76M | 70.77M | 14.99M | -2.15M | 4.28M | 0.39M | -10.39M | -18.31M | -3.69M | 6.00M | 1.35M | -11.19M | -3.06M | -1.54M | 2.43M | -9.17M | -2.20M | -1.50M | |||||||||
| Non Operating IncomeNon Op. Inc. | -81.26M | -99.75M | -91.64M | 113.81M | 28.20M | -127.38M | 30.12M | 102.50M | -29.37M | 104.69M | 69.50M | -75.25M | 71.28M | -27.16M | -99.75M | -117.16M | 17.06M | -32.47M | -94.78M | -51.63M | |||||||||
| Net income details | |||||||||||||||||||||||||||||
| EBT | 221.80M | 53.67M | 128.08M | 491.60M | 220.41M | -610.03M | 509.09M | 351.34M | 122.08M | 717.59M | -4.27M | 194.38M | 806.36M | 334.35M | 434.43M | 92.64M | 444.21M | 355.91M | 468.26M | 81.49M | |||||||||
| Profit After TaxPAT | 221.80M | 53.67M | 128.08M | 491.60M | 220.41M | -610.03M | 509.09M | 351.34M | 122.08M | 717.59M | -4.27M | 194.38M | 806.36M | 334.35M | 434.43M | 92.64M | 444.21M | 355.91M | 468.26M | 81.49M | |||||||||
| Income from Continuing OperationsIncome (Continuing) | 221.80M | 53.67M | 128.08M | 491.60M | 220.41M | -610.03M | 509.09M | 351.34M | 122.08M | 717.59M | -4.27M | 194.38M | 806.36M | 334.35M | 434.43M | 92.64M | 444.21M | 355.91M | 468.26M | 81.49M | |||||||||
| Consolidated Net IncomeConsol Net Inc. | 221.80M | 53.67M | 128.08M | 491.60M | 220.41M | -610.03M | 509.09M | 351.34M | 122.08M | 717.59M | -4.27M | 194.38M | 806.36M | 334.35M | 434.43M | 92.64M | 444.21M | 355.91M | 468.26M | 81.49M | |||||||||
| Income from Non-Controlling InterestsInc. Minority | 119.87M | 45.77M | 76.32M | 187.09M | 77.76M | -153.95M | 168.33M | 123.71M | 49.96M | 223.25M | -9.05M | 92.37M | 262.37M | 126.14M | 195.08M | 60.46M | 155.99M | 141.71M | 173.57M | 63.60M | |||||||||
| Income towards Parent CompanyParent Net Inc | 101.93M | 7.90M | 51.76M | 304.50M | 142.65M | -456.08M | 340.76M | 227.63M | 72.11M | 494.34M | 4.78M | 102.00M | 543.99M | 208.21M | 239.35M | 32.18M | 288.22M | 214.21M | 294.69M | 17.88M | |||||||||
| Net Income towards Common StockholdersNet Income | 101.93M | 7.90M | 51.76M | 304.50M | 142.65M | -456.08M | 340.76M | 227.63M | 72.11M | 494.34M | 4.78M | 102.00M | 543.99M | 208.21M | 239.35M | 32.18M | 288.22M | 214.21M | 294.69M | 17.88M | |||||||||
| Additional items | |||||||||||||||||||||||||||||
| EPS (Basic) | 0.24 | 0.02 | 0.12 | 0.70 | 0.32 | -1.04 | 0.76 | 0.51 | 0.16 | 1.10 | 0.01 | 0.23 | 1.22 | 0.46 | 0.55 | 0.08 | 0.67 | 0.50 | 0.67 | 0.04 | |||||||||
| EPS (Diluted) | 0.17 | 0.02 | 0.09 | 0.50 | 0.23 | -1.04 | 0.56 | 0.38 | 0.12 | 0.82 | 0.01 | 0.17 | 0.92 | 0.35 | 0.41 | 0.06 | 0.52 | 0.38 | 0.53 | 0.03 | |||||||||
| Weighted Average Shares OutstandingWtd. Avg. Shares | 428.23M | 414.79M | 433.96M | 436.32M | 439.29M | 437.96M | 445.61M | 450.41M | 448.44M | 447.60M | 448.62M | 451.02M | 447.63M | 448.19M | 435.48M | 423.51M | 431.89M | 429.80M | 436.79M | 445.06M | |||||||||
| Weighted Average Shares Outstanding (Diluted)Wtd. Avg. Shares (Dil.) | 607.17M | 414.80M | 607.20M | 607.21M | 607.23M | 437.97M | 607.25M | 605.86M | 601.14M | 602.90M | 597.48M | 596.91M | 592.73M | 594.11M | 578.10M | 562.30M | 559.61M | 564.46M | 556.84M | 556.90M | |||||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 607.17M | 607.18M | 607.18M | 607.22M | 607.22M | 607.22M | 607.23M | 601.82M | 598.39M | 597.44M | 597.44M | 594.39M | 589.18M | 589.11M | 566.46M | 583.17M | 579.02M | 577.11M | 576.19M | 575.00M | |||||||||
| Operating IncomeOp. Inc | 303.05M | 153.42M | 219.72M | 377.79M | 192.21M | -482.66M | 478.97M | 248.84M | 151.44M | 612.90M | -73.77M | 269.63M | 735.07M | 361.51M | 534.18M | 209.80M | 427.16M | 388.38M | 563.04M | 133.12M |
Pull Royalty Pharma's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=RPRX&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "RPRX", "statement": "IS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=RPRX&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();